Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison

Published:2017-01-19 Issue:6 Volume:77 Page:639-646
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Chopra Akhil¹,Georgieva Mina²,Lopes Gilberto³,Yeo Chong Ming¹,Haaland Benjamin²

Affiliation:

1. Department of Medical Oncology; Johns Hopkins Singapore International Medical Centre; Singapore

2. H. Milton Stewart School of Industrial and Systems Engineering; Georgia Institute of Technology; Georgia

3. Sylvester Comprehensive Cancer Center; University of Miami; Miami Florida

Publisher

Wiley

Subject

Urology,Oncology

Reference35 articles.

1. Cancer statistics;Jemal;CA: A Cancer Journal for Clinicians,2010

2. The dilemma of prostate cancer: A growing human and economic burden irrespective of treatment strategies;Borre;Acta Oncol,1997

3. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline;Loblaw;J Clin Oncol,2007

4. Hormonal therapy: Historical perspective to future directions;McLeod;Urology,2003

5. Management of patients with advanced prostate cancer: Recommendations of the St gallen advanced prostate cancer consensus conference (APCCC);Gillessen;Ann Oncol,2015

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer;JAMA Network Open;2024-08-16

2. Abiraterone Acetate Versus Enzalutamide Against Chemo-Naïve Castration-Resistant Prostate Cancer With Full-Dose Induction;Cureus;2024-07-10

3. Abiraterone acetate versus enzalutamide against chemo-naïve castration resistant prostate cancer with full dose induction;2024-04-18

4. Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2024-03-27

5. Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis;International Journal of Clinical Oncology;2023-12-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3